What is the prognosis for patients with MLH1 and MSH2 mutations?
The prognosis for patients with MLH1 and MSH2 mutations can vary depending on the type and stage of cancer. Generally, early detection and intervention can significantly improve outcomes. Regular surveillance and preventive measures, such as prophylactic surgeries, can also help manage the risk of developing cancer in individuals with these mutations. The use of targeted therapies and immunotherapies has further improved the prognosis for patients with cancers linked to MMR deficiencies.
